Crinetics Pharmaceuticals (CRNX) EBITDA (2017 - 2026)

Crinetics Pharmaceuticals' EBITDA history runs 10 years deep, the most recent figure standing at -$131.0 million for Q1 2026.

• In Q1 2026, EBITDA fell 36.8% year-over-year to -$131.0 million; the TTM figure through Mar 2026 stood at -$499.6 million (down 53.08% YoY), while the FY2025 annual figure was -$464.4 million, down 55.62% from the prior year.
• EBITDA was -$131.0 million for Q1 2026 at Crinetics Pharmaceuticals, down from -$123.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$36.4 million in Q1 2022 to a low of -$131.0 million in Q1 2026.
• Historically, EBITDA has averaged -$74.8 million across 5 years, with a median of -$67.8 million in 2024.
• The sharpest annual moves came in 2023 and 2025: EBITDA dropped 14.54% in 2023, then tumbled 73.62% in 2025.
• A 5-year view of EBITDA shows it stood at -$43.9 million in 2022, then sank by 32.66% to -$58.3 million in 2023, then sank by 40.19% to -$81.7 million in 2024, then plunged by 50.78% to -$123.1 million in 2025, then declined by 6.35% to -$131.0 million in 2026.
• The last three EBITDA figures came in at -$131.0 million (Q1 2026), -$123.1 million (Q4 2025), and -$129.5 million (Q3 2025), per Business Quant data.